Kasikara Canan, Kumar Sushil, Kimani Stanley, Tsou Wen-I, Geng Ke, Davra Viralkumar, Sriram Ganapathy, Devoe Connor, Nguyen Khanh-Quynh N, Antes Anita, Krantz Allen, Rymarczyk Grzegorz, Wilczynski Andrzej, Empig Cyril, Freimark Bruce, Gray Michael, Schlunegger Kyle, Hutchins Jeff, Kotenko Sergei V, Birge Raymond B
Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers University, New Jersey Medical School Cancer Center, Newark, New Jersey.
Advanced Proteome Therapeutics Corporation, Boston, Massachusetts.
Mol Cancer Res. 2017 Jun;15(6):753-764. doi: 10.1158/1541-7786.MCR-16-0350. Epub 2017 Feb 9.
Tyro3, Axl, and Mertk (collectively TAM receptors) are three homologous receptor tyrosine kinases that bind vitamin K-dependent endogenous ligands, Protein S (ProS), and growth arrest-specific factor 6 (Gas6), and act as bridging molecules to promote phosphatidylserine (PS)-mediated clearance of apoptotic cells (efferocytosis). TAM receptors are overexpressed in a vast array of tumor types, whereby the level of expression correlates with the tumor grade and the emergence of chemo- and radioresistance to targeted therapeutics, but also have been implicated as inhibitory receptors on infiltrating myeloid-derived cells in the tumor microenvironment that can suppress host antitumor immunity. In the present study, we utilized TAM-IFNγR1 reporter lines and expressed TAM receptors in a variety of epithelial cell model systems to show that each TAM receptor has a unique pattern of activation by Gas6 or ProS, as well as unique dependency for PS on apoptotic cells and PS liposomes for activity. In addition, we leveraged this system to engineer epithelial cells that express wild-type TAM receptors and show that although each receptor can promote PS-mediated efferocytosis, AKT-mediated chemoresistance, as well as upregulate the immune checkpoint molecule PD-L1 on tumor cells, Mertk is most dominant in the aforementioned pathways. Functionally, TAM receptor-mediated efferocytosis could be partially blocked by PS-targeting antibody 11.31 and Annexin V, demonstrating the existence of a PS/PS receptor (i.e., TAM receptor)/PD-L1 axis that operates in epithelial cells to foster immune escape. These data provide a rationale that PS-targeting, anti-TAM receptor, and anti-PD-L1-based therapeutics will have merit as combinatorial checkpoint inhibitors. Many tumor cells are known to upregulate the immune checkpoint inhibitor PD-L1. This study demonstrates a role for PS and TAM receptors in the regulation of PD-L1 on cancer cells. .
酪氨酸激酶受体3(Tyro3)、AXL受体酪氨酸激酶(Axl)和巨噬细胞表皮生长因子受体(Mertk,统称TAM受体)是三种同源受体酪氨酸激酶,它们能结合维生素K依赖性内源性配体——蛋白S(ProS)和生长停滞特异性因子6(Gas6),并作为桥梁分子促进磷脂酰丝氨酸(PS)介导的凋亡细胞清除(噬菌作用)。TAM受体在大量肿瘤类型中过度表达,其表达水平与肿瘤分级以及对靶向治疗的化学和放射抗性的出现相关,但也被认为是肿瘤微环境中浸润的髓系来源细胞上的抑制性受体,可抑制宿主抗肿瘤免疫。在本研究中,我们利用TAM-IFNγR1报告基因系,并在多种上皮细胞模型系统中表达TAM受体,以表明每个TAM受体对Gas6或ProS具有独特的激活模式,以及对凋亡细胞上的PS和PS脂质体活性具有独特的依赖性。此外,我们利用该系统构建表达野生型TAM受体的上皮细胞,并表明尽管每个受体都能促进PS介导的噬菌作用、AKT介导的化学抗性,以及上调肿瘤细胞上的免疫检查点分子程序性死亡受体配体1(PD-L1),但Mertk在上述途径中最为突出。在功能上,TAM受体介导的噬菌作用可被靶向PS的抗体11.31和膜联蛋白V部分阻断,这证明了上皮细胞中存在一个PS/PS受体(即TAM受体)/PD-L1轴,该轴可促进免疫逃逸。这些数据为基于靶向PS、抗TAM受体和抗PD-L1的疗法作为联合检查点抑制剂具有优势提供了理论依据。已知许多肿瘤细胞会上调免疫检查点抑制剂PD-L1。本研究证明了PS和TAM受体在癌细胞上PD-L1调节中的作用。